SpineOvations begins clinical study of DiscSeal for lumbar pain in Australia

Alan Condon -   Print  |

SpineOvations initiated a pilot clinical study of DiscSeal in patients suffering from lumbar spine pain after recently receiving Australian regulatory approval.

The first patient in the study was treated with DiscSeal at Waratah Private Hospital in Sydney.

The study will enroll six to 10 patients suffering from lumbar pain caused by discogenic disease who have not been treated properly by initial medical therapy.

DiscSeal is a viscous material that is injected percutaneously into the intervertebral diseased disc of patients suffering from lumbar pain under local anesthesia. SpineOvations aims to determine DiscSeal's safety and efficacy in reducing the patients' pre-treatment pain levels over a six-month period.

Data from the study will be used to support further studies in Europe and the U.S.

More articles on biologics:
Orthofix's M6-C cervical disc in 2019: 7 key developments
Dr. Robert Brady: How the 2020 CMS final rule will affect the spine field
How OrthoNY is trying to solve its recruiting problem

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers